JACC
HOME SUBSCRIPTIONS CURRENT ISSUE PAST ISSUES CARDIOSOURCE SEARCH HELP FEEDBACK
 QUICK SEARCH:   [advanced]


     


J Am Coll Cardiol, 2002; 39:1623-1629
© 2002 by the American College of Cardiology Foundation
This Article
Right arrow Abstract Freely available
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Johnson, W.
Right arrow Articles by Stevenson, L. W.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Johnson, W.
Right arrow Articles by Stevenson, L. W.

Neurohormonal activation rapidly decreases after intravenous therapy withdiuretics and vasodilators for class IV heart failure

Wendy Johnson, MD*, Torbjørn Omland, MD*, Christian Hall, MD{dagger}, Caroline Lucas, MD{ddagger}, Ole L. Myking, MD§, Caroline Collins, RN*, Marc Pfeffer, MD, FACC*, Jean-Lucien Rouleau, MD, FACC|| and Lynne W. Stevenson, MD, FACC*,*

* Brigham and Women’s Hospital, Cardiovascular Division, Harvard Medical School, Boston, Massachusetts, USA
{dagger} Research Institute for Internal Medicine, University of Oslo, Oslo, Norway
{ddagger} Rijnland Hospital, Leiderdorp, Netherlands
§ University Hospital of Bergen, Department of Clinical Chemistry, Division of Endocrinology, Bergen, Norway
|| Toronto General Hospital, University of Toronto, Cardiology Division, Toronto, Canada



View larger version (11K):

[in a new window]
 
Figure 1 Effect of therapy on plasma aldosterone levels (left) and plasma renin activity (right) before intervention (A), after intravenous vasodilators and diuretics (B) and after transition to an oral regimen, including captopril (C). *p < 0.05 compared to A.

 


View larger version (16K):

[in a new window]
 
Figure 2 Effect of therapy on plasma norepinephrine levels before intervention (A), after intravenous vasodilators and diuretics (B) and after transition to an oral regimen (C). *p < 0.05 compared to A.

 


View larger version (12K):

[in a new window]
 
Figure 3 Effect of therapy on plasma endothelin levels before intervention (A), after intravenous vasodilators and diuretics (B) and after transition to an oral regimen (C). *p < 0.05 compared to A.

 


View larger version (16K):

[in a new window]
 
Figure 4 Effect of therapy on plasma levels of atrial natriuretic peptide (ANP), B-type natriuretic peptide (BNP) (left), and N-terminal pro-ANP (N-ANP) (right) before intervention (A), after intravenous vasodilators and diuretics (B) and after transition to an oral regimen (C). *p < 0.05 compared to A.

 





HOME SUBSCRIPTIONS CURRENT ISSUE PAST ISSUES CARDIOSOURCE SEARCH HELP FEEDBACK
Copyright © 2002 by the American College of Cardiology Foundation.